Le Comité consultatif national sur les annexes de médicaments (CCNAM) a tenu une rencontre le 6 et7 juin 2021 et a proposé les recommandations provisoires suivantes (disponibles qu’en anglais) :

• Non-live recombinant herpes zoster vaccine – be granted Schedule II status
• Bisacodyl, when sold in strengths of 5mg or less per oral dosage unit, in package sizes containing no more than 105 mg of bisacodyl – be granted Unscheduled Status
• Bisacodyl, when sold in strengths of 10 mg or less per rectal dosage unit/suppository, in package sizes containing no more than 50 mg of bisacodyl – remain Unscheduled
• Bisacodyl and its salts, except when sold in strengths of 5 mg or less per oral dosage unit in package sizes containing no more than 105mg of bisacodyl and except when sold in strengths of 10mg or less per rectal dosage unit/suppository in package sizes containing no more than 50mg of bisacodyl – remain in Schedule III

L’ANORP doit recevoir toute objection à ces recommandations provisoires avant le 15 juillet 2021 en fin de journée. Veuillez envoyer toute question ou tout commentaire au secrétariat du CCNAM en écrivant à ndsac@napra.ca.